Oriola (OKDBV) Q3 2026 earnings summary

Executive summary

• Q3 net sales rose 5.1% to EUR 53.0m; adjusted EBITDA was unchanged YoY at EUR 9.6m as growth was offset by a one-off EUR 0.7m inventory provision.

• Commercial execution, operational improvements and higher volumes supported growth; supply-chain operations remained stable despite elevated inventories and capacity pressures.

• 9M adjusted EBITDA was EUR 25.3m; the period loss narrowed to EUR 1.3m from EUR 9.3m, while free cash flow turned negative amid working-capital outflows.

Financial highlights

• Q3 invoicing increased 3.4% to EUR 1,053.6m; net sales grew 5.1% to EUR 53.0m.

• 9M invoicing rose 5.6% to EUR 3,263.8m; net sales increased 1.6% to EUR 158.9m, or 4.1% excluding Swedish dose dispensing sales in Q1 2025.

• Q3 adjusted EBITDA was EUR 9.6m, flat YoY; reported EBITDA was EUR 6.1m versus EUR 7.0m, including EUR 3.5m of adjusting items.

• 9M EBITDA was EUR 15.3m versus EUR 14.5m; adjusted EBITDA was EUR 25.3m versus EUR 25.2m, including EUR 10.1m of adjusting items, mainly ERP costs.

• 9M result was EUR -1.3m versus EUR -9.3m and EPS was EUR -0.01 versus EUR -0.05; Q3 result was EUR 2.0m versus EUR 1.7m.

Outlook and guidance

• FY 2026 adjusted EBITDA is expected to increase from EUR 35.1m in 2025; outlook was reiterated on the basis of market growth and strategy execution.

• Sales growth is expected to continue in both segments; new distribution partnerships are expected to contribute positively from Q4.

• Efficiency savings and cost control are expected to support profitability; distribution markets are forecast to grow, led by high-value medicines and products requiring advanced logistics.